GUTS — FRACTYL HEALTH, INC.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1572616 ·
Last close
$0.92
Market Cap
$145.61M
52W High
$1.03
52W Low
$0.42
ADV30
2,244,173
Next earnings
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -20,820,000 9,218,000 99,385,000 63,168,000 78,008,000
Dec 2025 0 0 -23,284,000 -43,727,000 121,402,000 81,540,000 111,944,000
Sep 2025 0 0 -22,694,000 -45,603,000 114,272,000 77,657,000 117,450,000
Jun 2025 0 0 -26,079,000 -27,889,000 62,006,000 22,291,000 80,218,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-90,328,000
Investing CF
$-557,000
Financing CF
$104,961,000
CapEx
$-557,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-556,264,000
Inventory
$0
Receivables
$0
ST Investments
EBIT TTM
$-96,816,000
Pretax Income TTM
$-140,954,000
Interest Exp TTM
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -96,816,000 -140,954,000 121,402,000 111,944,000 -90,328,000
Dec 2024 93,000 -93,531,000 -68,694,000 108,077,000 79,653,000 -65,521,000
Dec 2023 120,000 -50,836,000 -77,091,000 76,212,000 401,274,000 -42,823,000
Dec 2022 0 -49,385,000 -46,453,000 60,956,000 313,275,000 -46,243,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.54

Peers — same industry

TickerNameMarket CapLastDaily %
STEX Streamex Corp. $147.03M $1.41
SNWV SANUWAVE Health, Inc. $139.82M $16.26
HYPR Hyperfine, Inc. $139.80M $1.66
NNOX Nano-X Imaging Ltd. $137.79M $1.98
CVRX CVRx, Inc. $161.34M $6.08

News headlines (Yahoo Finance, 1h cache)

Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround
2026-05-16 20:13 · Yahoo
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income
2026-05-14 13:19 · Yahoo
12 Health Care Stocks Moving In Wednesday's Intraday Session
2026-05-13 17:06 · Yahoo
Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ...
2026-05-13 05:02 · Yahoo
Fractyl Health Q1 Earnings Call Highlights
2026-05-13 00:25 · Yahoo
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
2026-05-12 20:05 · Yahoo
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
2026-05-11 11:00 · Yahoo
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
2026-05-11 10:00 · Yahoo
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
2026-05-05 11:00 · Yahoo
Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary
2026-03-25 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.